全球水痘病毒疫苗市场规模（依疫苗、应用、供应商、区域覆盖）预测（至 2025 年）

水痘疫苗的市场规模及预测

2024 年水痘病毒疫苗市场规模为 35.3652 亿美元，预计到 2032 年将达到 54.4344 亿美元，预测期内（2026-2032 年）的复合年增长率为 6.11%。

推动全球水痘病毒疫苗市场的因素

水痘病毒疫苗市场的驱动因素可能受到多种因素的影响。这些因素包括：

• 带状疱疹和水痘发病率不断上升。全球带状疱疹和水痘感染率不断上升，推动了对水痘病毒疫苗的需求。水痘传染性极强，尤其是在青少年中，曾经患过水痘的人也可能感染带状疱疹，因此接种疫苗对于预防这两种疾病至关重要。
• 政府免疫计划：水痘病毒疫苗接种率在很大程度上受到政府主导的免疫计划的影响，尤其是在已开发国家和开发中国家。儿童、青少年和成人的常规水痘疫苗接种通常被纳入国家免疫方案，增加了疫苗接种率和市场需求。
• 卫生当局的指南和建议：世界卫生组织 (WHO)、美国疾病管制与预防中心 (CDC) 以及其他国家卫生当局已发布指南和建议，支持使用水痘病毒疫苗作为预防水痘和带状疱疹的措施。医疗保健提供者对这些建议的遵守有助于市场成长。
• 由于疫苗技术的进步，包括重组疫苗和减毒活病毒疫苗的研发，水痘病毒疫苗如今更安全、更有效、更方便。近期製剂性能的提升正推动着市场的成长与渗透。
• 合併疫苗：患者和医护人员发现，合併疫苗可以预防多种可透过疫苗预防的疾病，例如水痘、麻疹、流行性腮腺炎和德国德国麻疹，更便捷，也提高了依从性。水痘病毒疫苗产业的成长部分得益于联合疫苗。
• 增强对疫苗接种益处的认知：增强对疫苗接种益处的认知，例如避免水痘相关併发症，例如脑炎、肺炎以及随后的细菌感染，将有助于提高个人和家长的疫苗接种率。公共卫生宣传活动和教育计画支持将疫苗接种作为一种预防措施。
• 提高免疫覆盖率：市场扩张的动力源自于提高免疫覆盖率的努力，尤其是在贫困人群和疾病高发生地区。水痘病毒疫苗接种已变得更加普及，透过有针对性的疫苗宣传活动、学校疫苗接种计划和推广活动，减少了疾病的传播。
• 疫苗接种的经济效益：水痘和带状疱疹疫苗接种可降低疾病治疗、住院和疾病导致的生产力损失等医疗成本，进而带来经济效益。卫生经济学研究表明，水痘病毒疫苗接种费用低廉，推动了市场扩张。
• 医疗保健支出不断增长：受人口增长、人口老化以及医疗基础设施建设等因素的影响，人们在疫苗接种等预防性医疗保健措施上的投资能力不断增强。医疗保健投资的增加推动了水痘病毒疫苗市场的成长。
• 全球努力预防疫苗可预防疾病：全球努力预防和控制水痘等疫苗可预防疾病，将对市场成长产生正面影响。各国政府、国际组织和疫苗製造商正在共同努力，使高风险地区更容易获得水痘疫苗接种。

限制全球水痘病毒疫苗市场的因素

有几个因素可能会对水痘病毒疫苗市场造成限製或挑战。这些因素包括：

• 疫苗接种覆盖率有限：目前已有水痘病毒疫苗接种，但不同族群和地区的疫苗接种率有差异。接种意愿、错误讯息以及对疫苗益处缺乏了解等因素可能会影响疫苗接种率和覆盖率。
• 监管挑战：获得水痘病毒疫苗的监管批准可能既困难又耗时。包括临床试验、上市后监测以及安全性和有效性评估在内的监管要求可能会增加疫苗研发和商业化所需的成本和时间。
• 疫苗分发和供应挑战：确保充足且稳定的疫苗供应以满足水痘病毒疫苗的需求可能颇具挑战性。生产延误、供应链中断以及分发问题都可能影响疫苗供应，尤其是在医疗资源和基础设施不足的地区。
• 生产成本高：生产水痘病毒疫苗需要专门的生产技术和严格的品管方法。高昂的生产成本（包括设施、设备和原料的投资）可能会影响疫苗的价格和供应，尤其是在中低收入国家。
• 低温运输需求：为了维持疫苗的功效和效力，水痘疫苗与许多其他疫苗一样，必须在整个低温运输中严格控制温度。低温运输物流，包括搬运、储存和运输，可能会给疫苗製造商和经销商带来物流挑战并增加成本。
• 来自替代疫苗的竞争：预防水痘的疫苗接种计划和替代疫苗对水痘病毒疫苗构成了威胁。某些国家决定使用可预防多种疾病的联合疫苗，可能会影响水痘疫苗市场的需求。
• 疾病流行病学和人口趋势：水痘是一种流行病学可能随时间和地区变化的疾病，其流行病学受人口密度、疫苗接种率和人口结构变化等多种因素的影响。水痘流行病学的变化和盛行率的下降可能会影响市场动态和疫苗接种需求。
• 疫苗安全问题：水痘病毒疫苗相关的不利事件和安全问题可能会损害大众对疫苗宣传活动的信心。解决安全问题、实施严格的上市后监测以及对医疗保健提供者和公众保持开放和诚实的态度，对于维持疫苗接种的接受度和普及度至关重要。
• 医疗预算限制：由于医疗目标相互衝突以及预算限制，政府对水痘疫苗接种计画的资金筹措和投入可能有限。财政资源不足可能阻碍弱势族群接种疫苗，阻碍提高疫苗接种覆盖率的努力。
• 大流行和感染疾病爆发是全球卫生紧急事件的例子，它们可能会扰乱常规疫苗接种计划，并挪用水痘疫苗接种工作的资金。公共卫生紧急事件也可能导致疫苗接种需求增加，给医疗保健系统和疫苗供应网络带来额外压力。

目录

第一章全球水痘病毒疫苗市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球水痘疫苗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球水痘病毒疫苗市场（依疫苗类型）

• 概述
• 单价水痘疫苗
• 水痘联合疫苗

6. 全球水痘病毒疫苗市场（依应用）

• 概述
• 水痘疫苗接种
• 带状疱疹疫苗接种
• 腮腺炎
• 麻疹
• 德国麻疹
• 水痘（MMRV）疫苗接种

7. 全球水痘病毒疫苗市场（依供应商）

• 概述
• 民众
• 私人的

8. 全球水痘病毒疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

9. 全球水痘病毒疫苗市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十章 公司简介

• Bio-Med Pvt. Limited
• Changchun BCHT Biotechnology Co. Ltd.
• Emcure Pharmaceuticals Limited
• GlaxoSmithKline plc
• Green Cross Holdings（GC Pharma）
• Merck & Co. Inc.
• Mitsubishi Chemical Holdings Corporation
• Novo Medi Sciences Pvt. Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited

第十一章 附录

• 相关调查

Varicella Virus Vaccine Market Size And Forecast

Varicella Virus Vaccine Market size was valued at USD 3536.52 Million in 2024 and is projected to reach USD 5443.44 Million by 2032, growing at a CAGR of 6.11% during the forecast period 2026-2032.

Global Varicella Virus Vaccine Market Drivers

The market drivers for the Varicella Virus Vaccine Market can be influenced by various factors. These may include:

• Growing Rates of Herpes Zoster and Varicella The need for varicella virus vaccines is driven by the rising global prevalence of herpes zoster and varicella infections. Because varicella is very communicable, especially in youngsters, and because those who have had varicella before might have herpes zoster, immunization is necessary to prevent both illnesses.
• Government Immunization Programs: The uptake of varicella virus vaccinations is largely influenced by government-led immunization programs, especially in industrialized and developing nations. Routine varicella vaccination for children, adolescents, and adults is frequently included in national immunization regimens, which boosts vaccine uptake and market demand.
• Health Authorities' Guidelines and Recommendations: The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other national health agencies have released guidelines and recommendations that support the use of varicella virus vaccines as a preventative measure against varicella and herpes zoster. Healthcare providers contribute to market growth by adhering to these recommendations.
• Varicella virus vaccines are now safer, more effective, and more convenient because to ongoing developments in vaccine technology, such as the creation of recombinant and live attenuated vaccines. Improved properties of more recent formulations boost market growth and uptake.
• Combination Vaccines: Patients and healthcare professionals find it more convenient and compliant when there are combination vaccines available that offer protection against several diseases, such as varicella, measles, mumps, rubella, and other diseases that can be prevented by vaccination. The varicella virus vaccine industry is growing in part because to combination vaccinations.
• Increasing Knowledge of the Benefits of Vaccination: Raising knowledge of the advantages of vaccination, such as its ability to avoid complications connected to varicella, such as encephalitis, pneumonia, and subsequent bacterial infections, promotes vaccination uptake in both individuals and parents. Campaigns for public health and educational programs support immunization as a preventative approach.
• Increasing Vaccination Coverage: Market expansion is fueled by initiatives to increase vaccination rates, especially in underprivileged groups and areas with high rates of disease. Varicella virus vaccinations are more widely available and disease transmission is decreased through targeted vaccination campaigns, school-based immunization programs, and outreach activities.
• Economic Benefits of Vaccination: By lowering healthcare expenses related to disease treatment, hospitalization, and lost productivity due to illness, vaccination against varicella and herpes zoster delivers financial benefits. Studies on health economics show that immunization against the varicella virus is affordable, which encourages market expansion.
• Growing Healthcare Expenditure: As a result of variables including population expansion, aging populations, and the development of a more advanced healthcare infrastructure, there is a greater ability to invest in preventative healthcare measures like vaccinations. Increased investment in healthcare facilitates the growth of the varicella virus vaccine market.
• Global Vaccine-Preventable Disease activities: Global activities to prevent and control vaccine-preventable diseases, such as varicella, have a positive impact on market growth. Governments, international organizations, and vaccine producers work together to make varicella virus vaccinations more accessible in high-risk areas.

Global Varicella Virus Vaccine Market Restraints

Several factors can act as restraints or challenges for the Varicella Virus Vaccine Market. These may include:

• Limited Vaccination Coverage: Although vaccinations against varicella virus are available, rates of vaccination may fluctuate throughout populations and geographical areas. Uptake and coverage rates can be hampered by elements including vaccine reluctance, false information, and a lack of understanding of the significance of immunization.
• Regulatory Difficulties: Getting regulatory clearance for vaccinations against the varicella virus can be difficult and time-consuming. The expense and time required for vaccine research and commercialization may increase due to regulatory requirements such as clinical trials, post-marketing surveillance, and safety and efficacy assessments.
• Problems with Vaccine Distribution and Supply: It can be difficult to guarantee a sufficient and steady supply of varicella virus vaccinations to satisfy demand. The availability of vaccines may be impacted by manufacturing setbacks, supply chain disruptions, and distribution issues, especially in areas with inadequate healthcare resources and infrastructure.
• High Manufacturing Costs: Specialized manufacturing techniques and strict quality control methods are required in the production of varicella virus vaccines. The price and accessibility of vaccines can be impacted by high manufacturing costs, which include investments in facilities, equipment, and raw materials, especially in low- and middle-income nations.
• Cold Chain Requirements: To preserve potency and efficacy, varicella virus vaccinations, like many others, need to be strictly temperature-controlled throughout the cold chain. Cold chain logistics, which include handling, storage, and transportation, can present logistical difficulties and raise expenses for producers and distributors of vaccines.
• Competition from Alternative vaccinations: Immunization plans for preventing varicella (chickenpox) and alternative vaccinations provide a threat to varicella viral vaccines. The market demand for stand-alone varicella vaccinations may be impacted by certain nations' decision to use combination vaccines, which provide protection against several diseases.
• Disease Epidemiology and Demographic Trends: Varicella (chickenpox) is a disease whose epidemiology can alter over time and between geographical areas due to a variety of factors, including population density, vaccine coverage rates, and demographic shifts. Varicella epidemiological shifts or declining disease prevalence might affect market dynamics and vaccination demand.
• Vaccine Safety Concerns: Adverse occurrences or safety concerns related to varicella virus vaccines have the potential to erode public confidence in immunization campaigns. Maintaining vaccination acceptance and uptake requires addressing safety concerns, carrying out stringent post-marketing surveillance, and being open and honest with healthcare practitioners and the general public.
• Healthcare Budget Restraints: Government financing and investment in varicella vaccination programs may be restricted due to competing healthcare objectives and budgetary restrictions. Inadequate financial resources may prevent underprivileged populations from getting vaccines and impede efforts to increase immunization rates.
• Pandemics and infectious disease outbreaks are examples of global health emergencies that might impede regular immunization programs and take funds away from efforts to vaccinate against varicella. Public health emergencies may also lead to a boost in vaccination demand, further taxing healthcare systems and vaccine supply networks.

Global Varicella Virus Vaccine Market Segmentation Analysis

The Global Varicella Virus Vaccine Market is Segmented on the basis of Vaccine Type, Application, End-User, and Geography.

Varicella Virus Vaccine Market, By Vaccine Type

• Monovalent Varicella Vaccine: A vaccine containing only the varicella zoster virus antigen, used for the prevention of varicella (chickenpox) infection.
• Combination Vaccines: Varicella vaccine may also be included in combination vaccines along with other antigens, such as measles, mumps, and rubella (MMR vaccine) or measles, mumps, rubella, and varicella (MMRV vaccine).

Varicella Virus Vaccine Market, By, Application

• Routine Immunization: Varicella vaccine is administered as part of routine childhood immunization schedules in many countries to prevent chickenpox.
• Outbreak Control: Varicella vaccine may be used in outbreak situations to control the spread of chickenpox in schools, communities, or other settings.
• Travel Vaccination: Varicella vaccine may be recommended for individuals traveling to regions where chickenpox is more common or for specific travel-related purposes.
• Post-Exposure Prophylaxis: Varicella vaccine may be given to susceptible individuals after exposure to varicella-zoster virus (VZV) to prevent or attenuate infection.

Varicella Virus Vaccine Market, By End-User

• Pediatric Clinics: Healthcare facilities specializing in pediatric care where varicella vaccine is administered to children as part of routine immunization schedules.
• Family Medicine Clinics: Healthcare facilities offering primary care services where varicella vaccine may be administered to children and adults.
• Public Health Departments: Government agencies responsible for public health initiatives, including vaccination programs and outbreak response.
• Travel Clinics: Specialty clinics providing travel-related health services where varicella vaccine may be offered to travelers.
• Pharmacies: Retail pharmacies or community health centers where varicella vaccine may be available for administration.

Varicella Virus Vaccine Market, By Geography

• North America: Includes the United States and Canada, where varicella vaccine is routinely administered as part of childhood immunization schedules.
• Europe: Includes countries such as Germany, the UK, France, Italy, and Spain, where varicella vaccine availability and usage may vary.
• Asia-Pacific: Includes countries such as China, Japan, India, and Australia, where varicella vaccine may be recommended for specific populations or in certain regions.
• Latin America: Includes countries such as Brazil, Mexico, and Argentina, where varicella vaccine may be included in national immunization programs.
• Middle East and Africa: Regions where varicella vaccine availability and usage may be limited or targeted towards specific populations.

Key Players

The "Global Varicella Virus Vaccine Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bio-Med Pvt. Limited, Changchun BCHT Biotechnology Co. Ltd., Emcure Pharmaceuticals Limited, GlaxoSmithKline plc, Green Cross Holdings (GC Pharma), Merck & Co. Inc., Mitsubishi Chemical Holdings Corporation, Novo Medi Sciences Pvt. Ltd., Sanofi, and Takeda Pharmaceutical Company Limited. The competitive landscape section includes key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally. Additionally, our market analysis includes a part devoted explicitly to these leading players. Our experts give an overview of each player's financial statements, product benchmarking, and SWOT analysis.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VARICELLA VIRUS VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VARICELLA VIRUS VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY VACCINE

• 5.1 Overview
• 5.2 Monovalent Varicella Vaccine
• 5.3 Combination Varicella Vaccine

6 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Chickenpox immunization
• 6.3 Herpes Zoster Immunization
• 6.4 Mumps
• 6.5 Measles
• 6.6 Rubella
• 6.7 Varicella (MMRV) Immunization

7 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY PROVIDER

• 7.1 Overview
• 7.2 Public Provider
• 7.3 Private Provider

8 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VARICELLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Bio-Med Pvt. Limited
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Changchun BCHT Biotechnology Co. Ltd.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Emcure Pharmaceuticals Limited
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 GlaxoSmithKline plc
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Green Cross Holdings (GC Pharma)
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Merck & Co. Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Development
• 10.7 Mitsubishi Chemical Holdings Corporation
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Novo Medi Sciences Pvt. Ltd.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Sanofi
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Development
• 10.10 Takeda Pharmaceutical Company Limited
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Development

11 Appendix

• 11.1 Related Research